Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.43 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.43 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | PRCP | P42785 | 12/20 | 0.41 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.39 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6122177 | 1.00 | CYP3A4 (0.43) | CYP3A4CYP2C9NR1I2ABCB11OPRK1 | |
| SCHEMBL14966582 | 0.84 | CYP3A4 (0.49) | CYP3A4CYP2C9NR1I2ABCB11OPRK1 | |
| SCHEMBL13505338 | 0.83 | PRCP (0.41) | CYP3A4CYP2C9NR1I2ABCB11OPRK1 | |
| SCHEMBL1293552 | 0.83 | PRCP (0.41) | CYP3A4CYP2C9NR1I2ABCB11OPRK1 | |
| SCHEMBL18727523 | 0.82 | PRCP (0.46) | CYP3A4CYP2C9NR1I2ABCB11OPRK1 | |
| SCHEMBL45280 | 0.82 | UCHL1 (0.44) | CYP3A4CYP2C9NR1I2ABCB11OPRK1 | |
| SCHEMBL2711186 | 0.82 | UCHL1 (0.44) | CYP3A4CYP2C9NR1I2ABCB11OPRK1 | |
| SCHEMBL2756354 | 0.82 | CYP3A4 (0.53) | CYP3A4CYP2C9NR1I2ABCB11OPRK1 | |
| SCHEMBL45250 | 0.82 | UCHL1 (0.44) | CYP3A4CYP2C9NR1I2ABCB11OPRK1 | |
| SCHEMBL3448550 | 0.81 | PRCP (0.55) | CYP3A4CYP2C9NR1I2ABCB11OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10766912-B2 | Silicon-containing compound for resistance to hepatitis C virus infection | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2020-09-08 | — | — | US | disclosed |
| EP-3604295-A1 | SILICON-CONTAINING COMPOUND FOR RESISTANCE TO HEPATITIS C VIRUS INFECTION | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2020-02-05 | — | — | EP | disclosed |
| WO-2012135581-A1 | METHODS FOR TREATING DRUG-RESISTANT HEPATITIS C VIRUS INFECTION WITH A 5,5-FUSED ARYLENE OR HETEROARYLENE HEPATITIS C VIRUS INHIBITOR | IDENIX PHARMACEUTICALS, INC. (US) | 2012-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10766912-B2 | Silicon-containing compound for resistance to hepatitis C virus infection | SLC11A2, SLC10A1, SLC39A11 | CYP3A4 474/4885CYP2C9 1933/4885NR1I2 621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.